ReviewFrontiers in neuroscience2021
Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation.
Review in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).Journal of neurology · 2025Trial
- Human biomarker navigator.iMeta · 2026Review
- A longitudinal study of CLDN5 DNA methylation and PTSD.Journal of behavioral medicine · 2026Article
- Selected Proteins Involved in the Neuropathology of ASD as the Candidates for Fluid Biomarkers.Molecules (Basel, Switzerland) · 2026Review
- Article
- Exercise Training and Biomarkers of Neuroaxonal Injury in Multiple Sclerosis: Narrative Review.International journal of environmental research and public health · 2026Review
- Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis.European journal of neurology · 2026Article
- Effectiveness of Risdiplam Treatment in Adult Patients With Spinal Muscular Atrophy Type IIb-III.Revista de neurologia · 2026Article
- HTLV-1-Specific CTL Accumulation in CSF Contributes to Neuroinflammation in HTLV-1-Associated Myelopathy.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Evaluating the potential of sNfL as a biomarker in MS management in the UK: insights from SUNLIT survey.BMC neurology · 2025Article
- Multiomics approach identifies SERPINB1 as candidate biomarker for spinocerebellar ataxia type 2.Scientific reports · 2025Article
- The Serum Lipid Profile of Relapsing Multiple Sclerosis Differs Reproducibly From Healthy Controls.Journal of neurochemistry · 2025Article
- Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice.International journal of molecular sciences · 2025Review
- Trends in clinical studies evaluating neurofilament light chain as a biomarker.Biomarkers in medicine · 2025Article
- Correlation of Neurodegenerative Biomarkers and Functional Outcome in Patients with Relapsing-Remitting Multiple Sclerosis.Neurology international · 2025Article
- The Association of Axonal Damage Biomarkers and Osteopontin at Diagnosis Could Be Useful in Newly Diagnosed MS Patients.Neurology international · 2025Article
- Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Advancements in multiple sclerosis.Internal medicine journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measurement of serum neurofilament light chain concentration (sNfL) promises to become a convenient, cost effective and meaningful adjunct for multiple sclerosis (MS) prognostication as well as monitoring disease activity in response to treatment. Despite the remarkable progress and an ever-increasing literature supporting the potential role of sNfL in MS over the last 5 years, a number of hurdles remain before this test can be integrated into routine clinical practice. In this review we highlight these hurdles, broadly classified by concerns relating to clinical validity and analytical validity. After setting out an aspirational roadmap as to how many of these issues can be overcome, we conclude by sharing our vision of the current and future role of sNfL assays in MS clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.